REVB — Revelation Biosciences Cashflow Statement
0.000.00%
- $2.74m
- -$11.81m
Annual cashflow statement for Revelation Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -2.53 | -12 | -10.8 | -0.12 |
Depreciation | ||||
Non-Cash Items | 0.029 | 0.523 | 0.316 | -8.17 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 1.08 | 0.356 | -0.731 | 0.982 |
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Accrued Expenses | ||||
Cash from Operating Activities | -1.42 | -11.1 | -11.2 | -7.29 |
Capital Expenditures | 0 | -0.132 | 0 | — |
Purchase of Fixed Assets | ||||
Cash from Investing Activities | 0 | -0.132 | 0 | — |
Financing Cash Flow Items | — | — | 11.5 | 0 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 5.91 | 8 | 15.2 | 14 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 4.49 | -3.22 | 3.98 | 6.74 |